Clinical Trial Update: A Phase II Trial of Regadenoson in Sickle Cell Anemia [Phase 2]

View source ↗

Summary

Phase II trial update for regadenoson in sickle cell anemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Regadenoson (Regadenoson)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Sickle Cell Anemia | Phase 2 | Status: COMPLETED | Results posted: 2018-02-07